138199-72-1

Basic information

• Product Name: (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (1:1)
• Synonyms: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (1:1); Levofloxacin hydrate
• CAS NO: 138199-72-1
• Molecular Formula: 2C₁₈H₂₀FN₃O₄*H₂O
• Molecular Weight: 379.3828
• Mol File: 138199-72-1.mol

Chemical Properties

• Boiling Point: 571.5°C at 760 mmHg
• Flash Point: 299.4°C
• Vapor Pressure: 6.7E-14mmHg at 25°C
• CAS DataBase Reference: (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (1:1)(138199-72-1)
• EPA Substance Registry System: (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (1:1)(138199-72-1)

Safety Data

• Hazardous Substances Data: 138199-72-1(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 100986-89-8 levofloxacin Q-acid 
• 177472-30-9 C₂₀H₂₄FN₃O₄ 

Relevant articles and documents

PROCESS FOR OBTAINING LEVOFLOXACIN FREE FROM SALTS

This invention relates to a process for obtaining levofloxacin free from salts. In this process the starting product used is the compound (V), alkaline hydrolysis of which within a water-(C1-C4)alcohol mixture, and subsequent neutralisation and separation of the salts, leads to levofloxacin free from salts. One characteristic of the process described is that no extractions are necessary in the final step of the process.

Preparation of levofloxacin and forms thereof

Levofloxacin was prepared by reacting (S)-(?)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid with N-methyl piperazine in a polar solvent or in a neat mixture to form levofloxacin. Further processing of the levofloxacin produced novel levofloxacin forms, including a hemihydrate and Forms A, B, C, F, G and H.

Methods for the purification of levofloxacin

Levofloxacin has been purified by dissolving levofloxacin in a polar solvent at an elevated temperature and crystallizing purified levofloxacin. Preferably, an antioxidant is added to increase the purity.